Catalysts / KLRA
Upcoming FDA decisions and readouts we track for Kailera Therapeutics, each with the filing that announced it.
FreeBioList tracks 4 upcoming catalysts for Kailera Therapeutics (KLRA, listed on Nasdaq). They cover 3 programmes: Ribupatide (KAI-9531) (Obesity (48-week high-dose trial); Obesity (global Phase 3)), KAI-7535 (Obesity) and KAI-4729 (Obesity).
First on the list: the Phase 2B readout for Ribupatide (KAI-9531) (Obesity (48-week high-dose trial)), guided by the company to Mid 2027. The furthest-out event tracked is 2028. By stage, the upcoming rows are 1 Phase 1 readout, 1 Phase 2 readout, 1 Phase 2B readout and 1 Phase 3 readout.
All 4 rows link to SEC filings (8-K or 6-K). All have been verified by a person reading the filing itself, most recently on 12 Sep 2026. The methodology page explains each status.
Background reading: Clinical trial phases explained: Phase 1 to Phase 4; How to read a Phase 3 topline readout.
| Company ▾ | Drug ▾ | Effect / indication | Next catalyst ▾ | Phase / type ▾ | Status ▾ | Source | Options |
|---|---|---|---|---|---|---|---|
| Kailera Therapeutics KLRA · Nasdaq | Ribupatide (KAI-9531) | Obesity (48-week high-dose trial) | Mid 2027 company guidance |
Phase 2B readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Kailera Therapeutics KLRA · Nasdaq | KAI-7535 | Obesity | 2027 company guidance |
Phase 2 readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Kailera Therapeutics KLRA · Nasdaq | KAI-4729 | Obesity | 2027 company guidance |
Phase 1 readout | Verified | 8-K exhibit 99.1 ↗ | No |
| Kailera Therapeutics KLRA · Nasdaq | Ribupatide (KAI-9531) | Obesity (global Phase 3) | 2028 company guidance |
Phase 3 readout | Verified | 8-K exhibit 99.1 ↗ | No |
FreeBioList